微生物
发表于 2025-3-26 22:37:28
http://reply.papertrans.cn/79/7808/780788/780788_31.png
nitric-oxide
发表于 2025-3-27 02:28:35
http://reply.papertrans.cn/79/7808/780788/780788_32.png
许可
发表于 2025-3-27 08:11:25
http://reply.papertrans.cn/79/7808/780788/780788_33.png
Medley
发表于 2025-3-27 13:12:19
http://reply.papertrans.cn/79/7808/780788/780788_34.png
Chagrin
发表于 2025-3-27 15:04:35
Quantitative Phenotypic Analysis of Drug Sequestering Macrophage Subpopulationsthogens, and other particles and produce immune effector cytokines. It has also been shown that macrophages sequester xenobiotics, particularly lysosomotropic agents. One of the well-known and best studied lysosomotropic agents is the weakly basic antibiotic clofazimine. Interestingly, not all macro
词汇
发表于 2025-3-27 17:47:59
Using an Integrated QSAR Model to Check Whether Small-Molecule Xenobiotics Will Accumulate in Biomemication, is described. The model can also be used to check whether .wanted membrane binding is likely to occur. Xenobiotics considered are fluorescent imaging probes, but the models can also be applied to substances used as biocides or pharmaceuticals. In addition to predicting the targeting of gene
你正派
发表于 2025-3-27 23:08:40
http://reply.papertrans.cn/79/7808/780788/780788_37.png
Ligneous
发表于 2025-3-28 03:00:51
Overcoming Cellular and Systemic Barriers to Design the Next Wave of Peptide Therapeuticsver 50 years, recent advances in understanding the additional target space afforded by peptide drugs, as well as technical achievements in peptide synthesis and screening have reinvigorated interest in peptide drugs as an addition to our therapeutic tool chest. Indeed, novel combinatorial strategies
一加就喷出
发表于 2025-3-28 07:31:09
http://reply.papertrans.cn/79/7808/780788/780788_39.png
伪证
发表于 2025-3-28 12:02:11
Cellular Trafficking of Monoclonal and Bispecific Antibodiesed for broad applications including agonizing or antagonizing cell surface receptors, bridging immune effector cells with cancer cells, and facilitating cell specific uptake of antibody–drug or antibody–oligonucleotide conjugates. Understanding the fate of antibodies and bispecific antibodies after